HealthEquity, Inc. (NASDAQ:HQY) Director Sells $2,418,000.00 in Stock

HealthEquity, Inc. (NASDAQ:HQY - Get Free Report) Director Stuart B. Parker sold 25,000 shares of the company's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $96.72, for a total value of $2,418,000.00. Following the completion of the sale, the director now owns 19,061 shares of the company's stock, valued at approximately $1,843,579.92. The trade was a 56.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

HealthEquity Trading Up 0.7 %

HealthEquity stock traded up $0.62 during midday trading on Friday, reaching $95.62. 631,708 shares of the stock traded hands, compared to its average volume of 634,230. The firm has a market cap of $8.29 billion, a PE ratio of 87.88, a price-to-earnings-growth ratio of 1.10 and a beta of 0.55. The company has a current ratio of 3.20, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. The company has a 50-day simple moving average of $93.81 and a two-hundred day simple moving average of $84.07. HealthEquity, Inc. has a 12-month low of $62.10 and a 12-month high of $105.82.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on HQY shares. JMP Securities upped their price objective on shares of HealthEquity from $105.00 to $107.00 and gave the company a "market outperform" rating in a report on Tuesday. Royal Bank of Canada increased their price target on shares of HealthEquity from $100.00 to $105.00 and gave the company an "outperform" rating in a research note on Tuesday. BTIG Research lifted their price target on shares of HealthEquity from $110.00 to $130.00 and gave the company a "buy" rating in a research report on Thursday, November 14th. Mizuho initiated coverage on HealthEquity in a research report on Wednesday, December 4th. They issued an "outperform" rating and a $126.00 price objective for the company. Finally, Bank of America raised their target price on HealthEquity from $100.00 to $120.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $110.71.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in HQY. International Assets Investment Management LLC purchased a new stake in HealthEquity during the 2nd quarter worth approximately $35,000. Paladin Wealth LLC acquired a new position in shares of HealthEquity in the third quarter worth $39,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of HealthEquity during the second quarter worth $73,000. GAMMA Investing LLC raised its stake in shares of HealthEquity by 57.8% in the third quarter. GAMMA Investing LLC now owns 939 shares of the company's stock valued at $77,000 after acquiring an additional 344 shares in the last quarter. Finally, Quarry LP raised its stake in shares of HealthEquity by 418.8% in the third quarter. Quarry LP now owns 1,349 shares of the company's stock valued at $110,000 after acquiring an additional 1,089 shares in the last quarter. Hedge funds and other institutional investors own 99.55% of the company's stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.